Priyanka  Sharma, MD

Priyanka Sharma, MD

University of Kansas Cancer Center

Professor of Medicine

Expertise: OncologyBreast CancerHematologic Cancers

Dr. Priyanka Sharma is an oncologist in Fairway, Kansas and is affiliated with University of Kansas Hospital. She received her medical degree from Baroda Medical College and has been in practice between 11-20 years.

Her specialties are: oncologists diagnose and treat cancers of all types. They use diagnostic tools like biopsies, endoscopies, X-ray and other imaging, nuclear medicine, and blood tests. Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors.

Priyanka Sharma, M.D., a breast cancer medical oncologist at The University of Kansas Cancer Center, has been named vice chair of SWOG’s Breast Committee.


Title

Cited By

Year

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer

523

2015

Abstract P5-13-03: Fulvestrant plus anastrozole as neoadjuvant therapy in postmenopausal women with hormone receptor positive early breast cancer

480

2016

Genome-wide association studies identify four ER negative-specific breast cancer risk loci

404

2013

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

334

2015

Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer

186

2010

Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer

176

2014

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing

141

2014

Biology and Management of Patients With Triple-Negative Breast Cancer

135

2016

19p13. 1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus

118

2012

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

88

2016

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

85

2016

Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohorts

80

2016

Reduction in Ki-67 in benign breast tissue of high-risk women with the lignan secoisolariciresinol diglycoside

53

2010

The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer

50

2014

Musculoskeletal adverse events associated with adjuvant aromatase inhibitors

50

2010

Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high …

36

2007

Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells

30

2012

Failure of high risk women to produce nipple aspirate fluid does not exclude detection of cytologic atypia in random periareolar fine needle aspiration specimens

28

2004

Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole: The VITAL trial

27

2012

Abstract P1-11-07: results of a Phase II study of neoadjuvant platinum/taxane based chemotherapy and erlotinib for triple negative breast cancer

22

2010

No Pitches / Articles Found

No Quotes

Available for logged-in users onlyLogin HereorRegister
close
0.07159